GEN-MKT-18-7897-A
Jul 10, 2026 | Blogs, Instrument maintenance, SCIEX OS software, Support, Technology | 0 comments
Analyst still works today; but is your LC-MS software ready for tomorrow’s regulated environment?
Analyst software has long been a trusted foundation in regulated LC-MS laboratories—and for many, it still performs reliably today. But regulated environments are evolving faster than ever. As labs transition to Windows 11, strengthen cybersecurity policies, modernize IT infrastructure, and prepare for future compliance expectations, software decisions are no longer just about what works today—they’re about managing tomorrow’s risk. Analyst will not be supported on Windows 11. While some labs may continue operating in unsupported environments temporarily, the bigger question is: when that risk becomes reality, will your lab be reacting under pressure—or executing a planned mitigation strategy with confidence?
Why LC-MS software is no longer “Just IT” in regulated environment
For many regulated laboratories, LC-MS software decisions have historically been treated as background infrastructure. Instruments matter. Methods matter. Validation matters. Software? Often assumed to be “good enough” as long as data can be acquired and processed in a compliant manner.
That assumption no longer holds.
Across regulated laboratories, teams are being asked to do more with fewer experts, tighter timelines, and higher scrutiny—without increasing risk. In that environment, software is no longer just a tool for acquisition. It has become a primary driver of productivity, consistency, and long-term compliance sustainability.
The hidden bottleneck in modern labs
Most labs today are not limited by instrument sensitivity or scan speed: they are limited by how workflows go through the lab.
Common symptoms include:
These issues don’t show up as instrument downtime. They show up as:
At the center of all of this is software—specifically, how much the software itself guides, constrains, or relies on the user.
Why “validated” does not always mean “optimized”
In regulated environments, stability is rightly valued. Validated systems protect data integrity and patient safety. But over time, many labs confuse validated with optimized.
A workflow can be validated and still:
When this happens, the lab compensates by adding:
All of these add operational friction. None of them improve scientific output.
The shift from expert-driven to system-driven labs
One of the most significant changes in regulated laboratories over the last decade is the availability of expertise.
Many labs are experiencing:
In this reality, software can no longer assume an expert user at every step. Instead, it must embed best practices, reduce decision fatigue, and enforce consistency by design.
This is not about “dumbing down” science. It is about ensuring that routine execution does not depend on heroic expertise.
Software as a compliance strategy—not a risk
Traditionally, software change has been viewed as a regulatory risk. Increasingly, forward-looking organizations are seeing the opposite: software modernization as a way to reduce long-term compliance burden.
Modern software platforms can:
Over time, this leads to fewer deviations, fewer corrective actions, and more predictable audits.
What does this mean for lab leadership
For leaders, the question is no longer:
“Does our software work?”
It is:
“Does our software scale, sustain, and protect us five years from now?”
Software decisions now affect:
In other words, LC-MS software has become a strategic lab decision, not an IT afterthought.
Why Analyst still works—and why that doesn’t mean it’s the future
Any serious discussion about LC-MS software modernization must start with an honest acknowledgment: Analyst software has earned its place in a regulated environment, and for decades it has been the backbone of validated LC-MS workflows. Many labs have built robust processes, training programs, and compliance frameworks around those validated workflows—and for good reason.
Recognizing what Analyst software does well is not a concession. It is a prerequisite for making smart, risk-based decisions about what comes next.
Why Analyst became the standard
Analyst succeeded because it delivered what regulated labs needed at the time:
In environments where workflows were executed by a small number of highly experienced scientists, Analyst enabled flexibility and precision.
For many labs, it still does.
Where Analyst continues to perform exceptionally well
Analyst remains a strong choice for:
In these scenarios, the cost of change may outweigh the benefit. Maintaining Analyst is often the right decision.
The difference between “working” and “sustaining”
However, the fact that Analyst works does not mean it is optimized for today’s lab realities.
Many organizations are discovering that:
Legacy software and the burden of expertise
Analyst assumes a knowledgeable user. In the past, that was a safe assumption. Today, it is often a liability and thus becomes a poor long-term strategy.
When software relies on expertise:
Over time, labs compensate with more controls—reviews, checklists, shadow SOPs (or varying SOP interpretations exist). These controls protect compliance but slow execution.
Why legacy does not mean obsolete—but it does mean limited
Calling Analyst “legacy” is not a judgment of quality. It is a statement of design era, which focused on:
Modern labs need systems that:
This gap is what drives the need for a new software model.
The real risk of unnecessary change
It is important to say this clearly: not every workflow needs to be migrated.
For some assays, staying on Analyst is the lowest-risk, highest-confidence choice. Forced modernization introduces:
Smart labs distinguish between workflows that must remain stable and workflows that can evolve.
Key Takeaways
Call to Action
Evaluate one of your routine LC-MS workflows and ask:
The objective is not to replace what works—it is to ensure your software strategy continues to support your laboratory as regulatory expectations; staffing models, and operational needs continue to evolve.
If you need more information, click here to contact our team.
Resources:
Analyst end-of-support resource center
Regulated laboratories are evolving faster than ever. New analytical modalities, higher sample throughput, increasing regulatory scrutiny, and leaner teams are reshaping how work gets done. At the same time, expectations for data integrity, standardization, and operational efficiency continue to increase complexity and/or scope. In this environment, LC-MS software is no longer simply an instrument control platform—it has become a critical part of a laboratory’s quality management system. The question is no longer whether your lab has changed, but whether your software has evolved to support the way regulated labs operate today, and if they are ready and able to meet the demands, they will face tomorrow.
As regulatory scrutiny increases and detection requirements tighten, laboratories are facing a new question: How can TFA be measured reliably, sensitively, and at scale?
Glycosylation is one of the more structurally diverse and biologically impactful PTMs in protein therapeutics. Both N‑linked and O‑linked glycans influence protein folding, stability, and biological activity. Given these effects on biotherapeutics, glycosylation is a closely monitored critical quality attribute (CQA). Comprehensive and site‑specific characterization of glycosylation is essential for informed decision‑making throughout drug discovery and development.
Posted by
You must be logged in to post a comment.
Share this post with your network